FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Advanced Breast Cancer
The FDA has approved Genentech's oral drug giredestrant, sold as Wilserdly, with everolimus for ESR1-mutated advanced breast cancer. In the evERA trial, median progression-free survival was 10 months versus 5.5 months, but overall survival data remain immature and the label is limited to ESR1-mutated disease.
FDA Approves Gazyva as First Drug for Primary Membranous Nephropathy
The FDA has approved Genentech's Gazyva for adults with primary membranous nephropathy, a rare autoimmune kidney disease with no previously approved drug. In a 142-patient trial, complete remission at two years was far more common than with tacrolimus, an off-label standard option.
Medtronic to Buy Contego Medical for $380 Million, Days After FDA Approves Its Carotid System
Medtronic plans to buy Contego Medical for $380 million plus undisclosed contingent payments. The deal adds a carotid stenting system with a built-in filter that the FDA approved days earlier, setting up direct competition with Boston Scientific in the growing field of transcarotid revascularization.
FDA Approves InspireMD’s CGuard Prime for TCAR, Six Months After a Delivery-System Recall
InspireMD has won FDA approval to use its CGuard Prime carotid stent in TCAR procedures, months after recalling the device's transfemoral delivery system. The pivotal study enrolled 50 patients with no comparison group, and the company has flagged substantial doubt about its ability to continue operating.
FDA Approves Talzenna Plus Xtandi Earlier in Metastatic Prostate Cancer With HRR Mutations
The FDA has approved Pfizer’s Talzenna with Xtandi for men with metastatic prostate cancer that still responds to hormone therapy and carries certain DNA-repair gene mutations. The combination roughly halved the risk of progression, but it caused frequent severe anemia, and survival data are not yet mature.